Papilozumib Vaginal Gel for Exocervical Mucosal Restoration in Women With Human Papillomavirus (HPV)
Key facts
- Who runs it
- Hifas da Terra S.L.
- Where
- Spain6 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Not yet recruiting
- People taking part
- 81 people, planned
- Starts
- Jul 2027
- Expected to end
- Dec 2027
- Type of study
- Interventional, 3 groupsOne group gets no study treatment, for comparison.
- Treatments tested
- Papilozumib vaginal gel
- Papilozumib oral supplement
- Record updated
- 5 October 2026
Who can take part
- Age
- 30 years to 50 years
- Sex
- Women only
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 21 criteriaShow less
Who can take part
- Female participant aged 30 to 50 years, inclusive
- Able to read and understand the participant information sheet and informed consent form
- Willing to participate and able to provide written informed consent
- Normal cervical cytology or cervical cytology showing atypical squamous cells of undetermined significance (ASC-US), low-grade squamous intraepithelial lesion (LSIL), or atypical glandular cells (AGC), with corresponding colposcopic findings at baseline
- Cervical cytology obtained no more than 3 months before the baseline/randomization visit
- Positive test for human papillomavirus (HPV) by polymerase chain reaction (PCR) at baseline
- HPV PCR test obtained no more than 3 months before the baseline/randomization visit
- Exocervical mucosal restoration score of 3 or lower on the 5-point colposcopic scale at baseline
- Baseline colposcopy performed no more than 3 months before randomization; the score may be determined from previously recorded images when available in the medical record
- Considered by the investigator able to follow the study instructions, attend the required visits, and complete the study assessments
Who cannot take part
- Clinically relevant immune-system disorder, autoimmune disease, or current treatment with immunosuppressive medication
- Systemic or local treatment with antibiotics, antifungal agents, or another treatment that may alter the microbiota within 4 weeks before baseline/randomization
- Undiagnosed abnormal genital bleeding during the 6 months before screening
- Surgical cervical excision within the previous year, cervical conization within the previous 6 months, or previous total hysterectomy
- Previous gynecological cancer
- Current participation in another clinical study or participation in another clinical study within 4 weeks before screening
- Planned surgery that could prevent adherence to the study treatment schedule
- Symptomatic vulvovaginal infection
- Contraindication to the vaginal gel or known allergy to any of its components
- Use of vaginal contraceptives or other vaginal hormonal treatments
- Pregnant, suspected to be pregnant, breastfeeding, or of childbearing potential and not using an effective contraceptive method
The main criteria, as questions
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 30 and 50 years old?
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This randomized, open-label, multicenter clinical study is designed to evaluate Papilozumib® vaginal gel in women aged 30 to 50 years who test positive for human papillomavirus (HPV) and present with either normal cervical cytology or cytological findings of atypical squamous cells of undetermined significance (ASC-US), low-grade squamous intraepithelial lesion (LSIL), or atypical glandular cells (AGC), accompanied by corresponding colposcopic findings.
Read full original descriptionShow less
Eighty-one participants will be randomly assigned in equal groups to receive either Papilozumib® vaginal gel, Papilozumib® vaginal gel plus an oral supplement, or standard clinical care without study treatment. All participants will be followed for six months.
The primary objective is to assess exocervical mucosa restoration 30 days after treatment initiation using a 5-point colposcopic scale. Additional assessments include cervical cytology, HPV clearance, vaginal health, treatment adherence, satisfaction, tolerability, safety, and exploratory analyses of the vaginal and intestinal microbiota.
The 3 groups in the trial
- Papilozumib vaginal gelTreatment being tested
Participants receive Papilozumib® vaginal gel for 6 months. During the first 3 months, one single-dose vaginal applicator is administered daily for 21 days followed by 7 days without treatment. During the following 3 months, one applicator is administered on alternate days, excluding menstrual periods
- Papilozumib vaginal gel plus oral supplementTreatment being tested
Participants receive Papilozumib® vaginal gel for 6 months using the same regimen as the vaginal-gel-only arm. Participants also receive oral Papilozumib® for 6 months, administered as two capsules while fasting and one capsule before dinner each day, separated from meals.
Treatment: Papilozumib vaginal gel and Papilozumib oral supplement
- Usual clinical practice without study treatmentNo study treatment, for comparison
Participants receive usual clinical practice without Papilozumib® vaginal gel or oral Papilozumib® supplementation. Participants undergo the study assessments and follow-up procedures specified in the protocol.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Exploratory, Randomized, Multicenter, Open-Label, Controlled, Parallel-Group Clinical Study to Evaluate the Efficacy of Papilozumib® Vaginal Gel in the Restoration of the Exocervical Mucosa
- Criteria questions
- Built from NCT07762209, who can take part
- Record updated
- 5 October 2026